CytoReason Ltd. announced that it will raise $20 million in a round of funding on September 20, 2022. The transaction will include participation from new investor, Pfizer Inc. The company will issue equity in the transaction.
Market Closed -
Other stock markets
|
After market 05:29:08 am | |||
28.88 USD | +0.66% | 28.98 | +0.33% |
24/05 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
23/05 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.31% | 163B | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- CytoReason Ltd. announced that it expects to receive $20 million in funding from Pfizer Inc.